255 related articles for article (PubMed ID: 10770540)
1. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy.
Soriano V; Dona C; Rodríguez-Rosado R; Barreiro P; González-Lahoz J
AIDS; 2000 Mar; 14(4):383-6. PubMed ID: 10770540
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
Weverling GJ; Mocroft A; Ledergerber B; Kirk O; Gonzáles-Lahoz J; d'Arminio Monforte A; Proenca R; Phillips AN; Lundgren JD; Reiss P
Lancet; 1999 Apr; 353(9161):1293-8. PubMed ID: 10218526
[TBL] [Abstract][Full Text] [Related]
3. Interruption of prophylaxis for major opportunistic infections in HIV-infected patients receiving triple combination antiretroviral therapy.
Jubault V; Pacanowski J; Rabian C; Viard JP
Ann Med Interne (Paris); 2000 May; 151(3):163-8. PubMed ID: 10896967
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy.
Schneider MM; Borleffs JC; Stolk RP; Jaspers CA; Hoepelman AI
Lancet; 1999 Jan; 353(9148):201-3. PubMed ID: 9923876
[TBL] [Abstract][Full Text] [Related]
5. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
[TBL] [Abstract][Full Text] [Related]
7. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?
Kirk O; Lundgren JD; Pedersen C; Nielsen H; Gerstoft J
AIDS; 1999 Sep; 13(13):1647-51. PubMed ID: 10509565
[TBL] [Abstract][Full Text] [Related]
8. A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 x 106 /l.
Koletar SL; Heald AE; Finkelstein D; Hafner R; Currier JS; McCutchan JA; Vallee M; Torriani FJ; Powderly WG; Fass RJ; Murphy RL;
AIDS; 2001 Aug; 15(12):1509-15. PubMed ID: 11504983
[TBL] [Abstract][Full Text] [Related]
9. A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapy.
Green H; Hay P; Dunn DT; McCormack S;
HIV Med; 2004 Jul; 5(4):278-83. PubMed ID: 15236617
[TBL] [Abstract][Full Text] [Related]
10. Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy: secondary prophylaxis.
Abgrall S; Matheron S; Le Moing V; Dupont C; Costagliola D;
J Acquir Immune Defic Syndr; 2001 Feb; 26(2):151-8. PubMed ID: 11242182
[TBL] [Abstract][Full Text] [Related]
11. Opportunistic infections occurring during highly active antiretroviral treatment.
Michelet C; Arvieux C; François C; Besnier JM; Rogez JP; Breux JP; Souala F; Allavena C; Raffi F; Garre M; Cartier F
AIDS; 1998 Oct; 12(14):1815-22. PubMed ID: 9792382
[TBL] [Abstract][Full Text] [Related]
12. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.
Jones JL; Hanson DL; Dworkin MS; Alderton DL; Fleming PL; Kaplan JE; Ward J
MMWR CDC Surveill Summ; 1999 Apr; 48(2):1-22. PubMed ID: 12412613
[TBL] [Abstract][Full Text] [Related]
13. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
[TBL] [Abstract][Full Text] [Related]
14. I hear you knockin' (but you can't come in): potent new HIV therapies are shutting out opportunistic infections.
Fichtenbaum CJ
Res Initiat Treat Action; 1998 Jul; 4(4):3-7. PubMed ID: 11365645
[TBL] [Abstract][Full Text] [Related]
15. Disseminated mycobacterium avium-intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated?
Lange CG; Woolley IJ; Brodt RH
Drugs; 2004; 64(7):679-92. PubMed ID: 15025543
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
[TBL] [Abstract][Full Text] [Related]
17. Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy.
Shafran SD; Mashinter LD; Phillips P; Lalonde RG; Gill MJ; Walmsley SL; Toma E; Conway B; Fong IW; Rachlis AR; Williams KE; Garber GE; Schlech WF; Smaill F; Pradier C
Ann Intern Med; 2002 Nov; 137(9):734-7. PubMed ID: 12416943
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators.
Yangco BG; Von Bargen JC; Moorman AC; Holmberg SD
Ann Intern Med; 2000 Feb; 132(3):201-5. PubMed ID: 10651600
[TBL] [Abstract][Full Text] [Related]
19. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy.
Dankner WM; Lindsey JC; Levin MJ;
Pediatr Infect Dis J; 2001 Jan; 20(1):40-8. PubMed ID: 11176565
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.
Currier JS; Williams PL; Koletar SL; Cohn SE; Murphy RL; Heald AE; Hafner R; Bassily EL; Lederman HM; Knirsch C; Benson CA; Valdez H; Aberg JA; McCutchan JA
Ann Intern Med; 2000 Oct; 133(7):493-503. PubMed ID: 11015162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]